Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?
Journal Title: Viral Hepatitis Journal - Year 2017, Vol 23, Issue 2
Abstract
Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests. However, these tests are either expensive or invasive. A new and more practical marker is needed. We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA. Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients. Serum ALT, HBsAg and HBeAg levels and HBV DNA levels were recorded. The results were analysed with the Mann-Whitney U test and Spearman correlation coefficient. A p value of ≤0.05 was considered statistically significant. Sequential results were compared using Blant-Alpman plot. Results: The patients were grouped as HBeAg-positive (37.2%) and HBeAg-negative (62.8%). Serum ALT levels were elevated in 82% of HBeAg-positive and 70.2% of HBeAg-negative subjects. There was a statistically significant difference in HBsAg levels between the groups (p<0.05). However, there was no statistically significant difference in ALT and HBV DNA levels (p>0.05). A statistically significant negative correlation was detected between HBsAg and HBV DNA levels in HBeAg-positive patients. No correlation was found between HBsAg and HBV DNA levels in HBeAg-negative subjects (p<0.05). In both HBeAg-positive and -negative individuals, there was a positive correlation between serum ALT and HBV DNA levels (p<0.05). Blant-Alpman graph did not show an appropriate profile. Conclusion: We found a negative correlation between HBsAg and HBV DNA levels in HBeAg-positive patients. However, this correlation is not practical in monitoring treatment response and replication.
Authors and Affiliations
Emel UZUNOĞLU, Ahmet Melih ŞAHİN, Esin AVCI, Hakan KUTLU, Gökçe Gökçe GÜNTEPE
Keywords
Related Articles
- EP ID EP251836
- DOI 10.4274/vhd.73645
- Views 66
- Downloads 0
Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection
Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is un...
An Important Financial Burden: Unnecessary Test Requests for Viral Hepatitis
Editorial
The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy
Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, pat...
TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C
Objective: We aimed to review the influence of host genetic factors on the clinical course, treatment response as well as fibrosis progression in patients with viral hepatitis C genotype 1. Materials and Methods: Ninety...
Are Liver Transaminases and Hepatitis C Virus-RNA Viral Loads Reliable Markers for Estimating Liver Fibrosis in Patients Recently Diagnosed with Hepatitis C? Evaluation of the Data of Ninety-five Young and Middle-aged Males in a Genotype-1b Prevalent Country
Objectives: Although liver biopsy is an invasive test, it is still considered as the gold standard method for determining the severity of liver diseases. Materials and Methods: A total of 95 young and middle-aged male pa...